Head to head
Semaglutide against Orforglipron
The same receptor reached two ways: a weekly injection that is a peptide, and a daily tablet that is a small molecule, which is what makes an oral version possible at all. Orforglipron was approved as Foundayo on 1 April 2026, so this is now approved against approved rather than approved against pipeline, and no trial has put the two head to head.
Column A
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Column B
OrforglipronOrforglipron (Foundayo, oral non-peptide GLP-1 agonist)
A once-daily GLP-1 pill rather than a shot, a small molecule rather than a peptide, FDA-approved on April 1, 2026 as Foundayo for weight management.
Side by side, on the facts we can check
| Attribute | Semaglutide | Orforglipron |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) | FDA-approved April 1, 2026 as Foundayo for chronic weight management (boxed thyroid C-cell warning) |
| Half-life | ~7 days | ~29-49 hours |
| Molecular weight | 4,113.6 Da | ~735 Da |
| Mechanism | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. | Activates the GLP-1 receptor as an orally available small molecule, reducing appetite and improving glucose-dependent insulin secretion. |
| Human studies cited | 5 | 5 |
| Legal status, US | FDA-approved, prescription only | FDA-approved (Foundayo, chronic weight management), prescription only |
Frequently asked questions
What is the difference between Semaglutide and Orforglipron?
Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction. Orforglipron: A once-daily GLP-1 pill rather than a shot, a small molecule rather than a peptide, FDA-approved on April 1, 2026 as Foundayo for weight management.
Which has stronger research evidence, Semaglutide or Orforglipron?
This database does not grade compounds. It counts what was run in people: 5 of the 5 studies cited on the Semaglutide profile were human work, against 5 of 5 for Orforglipron. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Semaglutide and Orforglipron FDA-approved?
Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management). Orforglipron: FDA-approved April 1, 2026 as Foundayo for chronic weight management (boxed thyroid C-cell warning).
Related posts
Blog articles that cover Semaglutide or Orforglipron, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.